GSK's Dovato meets primary goal in late-stage HIV study
In this article:
July 10 (Reuters) - British Drugmaker GlaxoSmithKline Plc on Wednesday said its two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients for 48 weeks at similar levels as the patients' previous three-drug treatment.
The company's HIV drugs division ViiV said the late stage study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults who switched to the regimen from at least a triple combination TAF-containing treatment.
Pfizer Inc and Shionogi & Co Ltd have small stakes in ViiV. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)
